13F-HR filed by Cutter Capital Management, LP
Cutter Capital Management, LP filed this 13F-HR for the quarter ended 2025-03-31, filed 2025-05-15, with 21 holding rows worth $229,647,548.
- Accession
- 0001214659-25-007818
- Filer
- CIK 1983313
- Filed
- 2025-05-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2025
A holdings report, 21 entries on the cover page, a total value of $229,647,548 stated on the cover page (in dollars after the unit check, H1), rows summing to $229,647,548 with VALUE read as dollars as filed, 13F file number 028-23904. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | 110122108 | COM | 295,000 | $17,992,050 | dollars as filed | |
| Amgen Inc. | 031162100 | COM | 50,000 | $15,577,500 | dollars as filed | |
| BIOGEN INC COM | 09062X103 | Stock | 113,500 | $15,531,340 | dollars as filed | |
| Eli Lilly and Company | 532457108 | COM | 18,000 | $14,866,380 | dollars as filed | |
| INSMED INC COM PAR $.01 | 457669307 | Stock | 186,384 | $14,219,235 | dollars as filed | |
| ULTRAGENYX PHARMACEUTICAL IN | 90400D108 | COM | 379,303 | $13,734,562 | dollars as filed | |
| BRIDGEBIO PHARMA INC | 10806X102 | COM | 390,644 | $13,504,563 | dollars as filed | |
| PERRIGO CO PLC SHS | G97822103 | Stock | 479,517 | $13,445,657 | dollars as filed | |
| ROIVANT SCIENCES LTD | G76279101 | SHS | 1,300,000 | $13,117,000 | dollars as filed | |
| TEVA PHARMACEUTICAL INDS LTD SPONSORED ADS | 881624209 | ADR | 801,806 | $12,323,758 | dollars as filed | |
| ROYALTY PHARMA PLC | G7709Q104 | SHS CLASS A | 356,894 | $11,110,110 | dollars as filed | |
| TARSUS PHARMACEUTICALS INC | 87650L103 | COMMON STOCK | 205,000 | $10,530,850 | dollars as filed | |
| VERONA PHARMA PLC | 925050106 | SPONSORED ADS | 160,000 | $10,158,400 | dollars as filed | |
| MADRIGAL PHARMACEUTICALS INC COM | 558868105 | Stock | 24,000 | $7,949,520 | dollars as filed | |
| SUMMIT THERAPEUTICS INC | 86627T108 | COM | 400,000 | $7,716,000 | dollars as filed | |
| HALOZYME THERAPEUTICS INC COM | 40637H109 | Stock | 120,000 | $7,657,200 | dollars as filed | |
| CYTOKINETICS INC | 23282W605 | COM NEW | 175,000 | $7,033,250 | dollars as filed | |
| AGIOS PHARMACEUTICALS INC | 00847X104 | COM | 235,350 | $6,895,755 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 418,127 | $6,012,666 | dollars as filed | |
| ARCUS BIOSCIENCES INC | 03969F109 | COM | 731,818 | $5,744,771 | dollars as filed | |
| NEWAMSTERDAM PHARMA CO NV | N62509109 | COMMON STOCK | 221,152 | $4,526,981 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001214659-25-007818 | this filing | 2025-05-15 | acceptance time not in the bulk data set |